veratrilogenin: from roots of Veratrilla baillinii Franch.; structure given in first source
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Veratrilla | genus | [no description available] | Gentianaceae | A plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 5490798 |
CHEMBL ID | 4100829 |
MeSH ID | M0098183 |
Synonym |
---|
veratrilogenin |
1,7-dihydroxy-3,4-dimethoxyxanthen-9-one |
1,7-dihydroxy-3,4-dimethoxy-xanthone |
9h-xanthen-9-one, 1,7-dihydroxy-3,4-dimethoxy- |
76907-77-2 |
1,7-dihydroxy-3,4-dimethoxyxanthone |
DTXSID70227707 |
CHEMBL4100829 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1434700 | Cytotoxicity against human MCF7/ADR cells measured after 48 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | Structure-activity relationships of diverse xanthones against multidrug resistant human tumor cells. |
AID1434698 | Cytotoxicity against Taxol-resistant human SMMC7721 cells measured after 48 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | Structure-activity relationships of diverse xanthones against multidrug resistant human tumor cells. |
AID1434699 | Cytotoxicity against Taxol-resistant human A549 cells measured after 48 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | Structure-activity relationships of diverse xanthones against multidrug resistant human tumor cells. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |